Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast

NCT04551495 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT04551495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04551495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Unknown status
Start date
January 14, 2021
Completion date
January 31, 2025
Enrollment
65 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

er+ breast cancer, her2-negative breast cancer, invasive lobular breast carcinoma